JP5256042B2 - 癌の処置のための併用療法 - Google Patents

癌の処置のための併用療法 Download PDF

Info

Publication number
JP5256042B2
JP5256042B2 JP2008542425A JP2008542425A JP5256042B2 JP 5256042 B2 JP5256042 B2 JP 5256042B2 JP 2008542425 A JP2008542425 A JP 2008542425A JP 2008542425 A JP2008542425 A JP 2008542425A JP 5256042 B2 JP5256042 B2 JP 5256042B2
Authority
JP
Japan
Prior art keywords
cancer
mpi
patient
term
hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008542425A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009516747A5 (enExample
JP2009516747A (ja
Inventor
ジョーダン・エス・フライドマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of JP2009516747A publication Critical patent/JP2009516747A/ja
Publication of JP2009516747A5 publication Critical patent/JP2009516747A5/ja
Application granted granted Critical
Publication of JP5256042B2 publication Critical patent/JP5256042B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2008542425A 2005-11-22 2006-11-21 癌の処置のための併用療法 Expired - Fee Related JP5256042B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73891905P 2005-11-22 2005-11-22
US60/738,919 2005-11-22
PCT/US2006/045151 WO2007062093A2 (en) 2005-11-22 2006-11-21 Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor

Publications (3)

Publication Number Publication Date
JP2009516747A JP2009516747A (ja) 2009-04-23
JP2009516747A5 JP2009516747A5 (enExample) 2010-01-14
JP5256042B2 true JP5256042B2 (ja) 2013-08-07

Family

ID=37994504

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008542425A Expired - Fee Related JP5256042B2 (ja) 2005-11-22 2006-11-21 癌の処置のための併用療法

Country Status (5)

Country Link
US (1) US8324194B2 (enExample)
EP (1) EP1951242A2 (enExample)
JP (1) JP5256042B2 (enExample)
CA (1) CA2628747C (enExample)
WO (1) WO2007062093A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089294A2 (en) 2003-04-04 2004-10-21 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
EP1622569B1 (en) 2003-04-24 2015-12-02 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metallproteases
EP2264030A1 (en) * 2003-10-17 2010-12-22 Incyte Corporation Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
WO2007016597A2 (en) * 2005-07-29 2007-02-08 The Regents Of The University Of California Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
US7910108B2 (en) 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
SI2242771T1 (sl) 2007-12-14 2013-09-30 Bristol-Myers Squibb Company Vezane molekule k humanemu ox40 receptorju
US20100332417A1 (en) * 2009-06-02 2010-12-30 Targeted Molecular Diagnostics, Llc Methods for the detection and quantitation of the p95 component of her2/neu (erbb2)
WO2011083391A2 (en) 2010-01-05 2011-07-14 Pfizer Inc. Biomarkers for anti-igf-ir cancer therapy
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
HRP20170411T1 (hr) 2012-03-02 2017-06-16 Genentech, Inc. Amido spirocilični amidni i sulfonamidni derivati
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
PL2844282T3 (pl) 2012-05-04 2019-11-29 Pfizer Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
RS57840B1 (sr) 2013-03-18 2018-12-31 Biocerox Prod Bv Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe
US20160060288A1 (en) * 2013-04-18 2016-03-03 Xi'anlibang Pharmaceutical Technology Co., Ltd. Ester derivatives of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-estra-1,3,5(10)-triene-3,17beta-diol having anticancer activity and preparation method thereof
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
EP4149547A4 (en) 2020-05-13 2024-08-14 Adagene AG Compositions and methods for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy
JP2004508334A (ja) * 2000-09-08 2004-03-18 フアルマシア・イタリア・エツセ・ピー・アー 化学予防剤としてのエクセメスタン
EP1377298B1 (en) 2001-01-26 2006-08-30 Pfizer Italia S.r.l. Exemestane for treating hormono-dependent disorders
WO2004089294A2 (en) * 2003-04-04 2004-10-21 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
EP1622569B1 (en) * 2003-04-24 2015-12-02 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metallproteases
EP2264030A1 (en) * 2003-10-17 2010-12-22 Incyte Corporation Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
WO2005117882A2 (en) * 2004-04-20 2005-12-15 Incyte Corporation Hydroxamic acid derivatives as metalloprotease inhibitors
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases

Also Published As

Publication number Publication date
EP1951242A2 (en) 2008-08-06
CA2628747C (en) 2014-01-21
US8324194B2 (en) 2012-12-04
CA2628747A1 (en) 2007-05-31
US20070117809A1 (en) 2007-05-24
JP2009516747A (ja) 2009-04-23
WO2007062093A3 (en) 2008-10-23
WO2007062093A2 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
US8324194B2 (en) Combination therapy for the treatment of cancer
AU2020201074B2 (en) Dual NK-1/NK-3 Receptor Antagonists For The Treatment Of Sex-Hormone-Dependent Diseases
JP6920709B2 (ja) ベンゾチオフェン系選択的エストロゲン受容体ダウンレギュレーター
EP3695839A1 (en) Therapeutic agent for solid cancers, which contains axl inhibitor as active ingredient
WO2000035455A1 (en) Heteroaryl-aryl ureas as igf-1 receptor antagonists
EP1343779B1 (en) Novel compounds
TR201802093T4 (tr) Terapötik terapilerde kullanım için akt inhibitör bileşiği ve abirateron kombinasyonu.
ES3043682T3 (en) Treatment of neuroepithelial tumors using selective glucocorticoid receptor modulators
CZ20021746A3 (cs) Nové sloučeniny
EP2747571A1 (en) Low-dose combination chemotherapy
CN102066367A (zh) 噻唑基哌啶衍生物
EP3191087A1 (en) Compositions and methods for treatment of prostate carcinoma
CN104349779A (zh) Pi-3激酶抑制剂的剂量方案
CA2831932A1 (en) Combinations of akt and mek inhibitor compounds, and methods of use
JP2009516747A5 (enExample)
US20240016811A1 (en) Cancer therapy using a combination of cdk7 inhibitor with an anti-microtubule agent
JP2010513446A (ja) 癌の治療に使用されるｍｅｋ阻害剤とｓｒｃキナーゼ阻害剤ａｚｄ０５３０との組み合わせ
US20230000876A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
US20240277722A1 (en) Cancer therapy using a combination of cdk7 inhibitor with an anti-cancer agent
JPWO2004035089A1 (ja) ホルモン依存性癌の治療剤
JP6748704B2 (ja) 抗癌治療剤
CN102227227A (zh) 包含吡啶并[4，3-d]嘧啶衍生的HSP90抑制剂和HER2抑制剂的药物组合
EP3858811A1 (en) N-aromatic amides compound and preparation method and use thereof
CN101863903B (zh) 1,4-二氢噻吩并[3’,2’:5,6]噻喃并[4,3-c]吡唑-3-羧酸衍生物及其应用
JP7130180B2 (ja) 子宮内膜症の処置のためのインドールの新規誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120815

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130215

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130326

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130422

R150 Certificate of patent or registration of utility model

Ref document number: 5256042

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160426

Year of fee payment: 3

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees